Introduction {#S1}
============

In 2004, the Infectious Disease Society of America (IDSA) reported that each year 90,000 of the two million people who acquired hospital bacterial infections died, a 4.5% mortality rate during hospitalization.^[@R1]^ Multi-drug resistant bacterial strains are a major problem that has been increasing very rapidly every year during the last few decades.^[@R2],[@R3]^ Since first reported in 1961, the incidence of methicillin-resistant *Staphylococcus aureus* (MRSA) has increased and accounted for more than 50% of *S. aureus* patient isolates in ICUs (intensive care units) within the National Nosocomial Infection Surveillance (NNIS) System by 1999. By 2003, 59.5% of isolates were MSRA.^[@R4],[@R5]^ Vancomycin resistant enterococci (VRE) has had a similar rapid rise in hospital isolates increasing from its discovery in 1986 to 25% of all enterococal isolates in 1999 and then increasing further to 28.3% by 2003 in NNIS surveyed ICUs.^[@R6]^ It is apparent that without the introduction of new antibiotics, this rise in multi-drug resistant strains will continue exposing hospital patients to undue risk of infection and possible death. These alarming statistics motivated a broad screen of compounds generated in our laboratory against MRSA and various "hits' were revealed in a screening collaboration with Achillion Pharmaceuticals. Among the scaffolds discovered were synthetically intensive quinolone-cephalosporins conjugates^[@R7]^ as well as various other scaffolds, all of which bore a reducible moiety. One synthetically attractive compound (**1**) was a low molecular weight nitrofuran benzimidazole with surprising potency against a number of important pathogens ([Table 1](#T1){ref-type="table"}). Herein we describe our efforts to rapidly generate structure activity relationships (SAR) from compound (**1**) utilizing commercially available diamines and the assessment of these agents as cost effective antibiotics against drug resistant MRSA strains. Only the active compounds are described in this manuscript as analogs in which the nitro was missing or replaced by a bromide or sulfonic acid (SO~3~H), as well as benzimidazoles bearing a methyl ester, carboxylic acid or guanidine, were all inactive (\>64 µg/ml, data not shown).

The only three approved nitrofuran-containing drugs (nitrofurantoin CAS \# 67-20-9, furazolidone CAS \# 67-45-8, and nitrofurazone CAS \# 59-87-0) that are on the market to treat various infections (urinary tract, gastrointestinal and skin, respectively) are shown in [Figure 1](#F1){ref-type="fig"}. All three are hydrazine derivatives, but many other preclinical nitrofuran based agents have since emerged. For instance, Lee *et. al.*, formerly at the University of Tennessee, demonstrated that various nitrofuran amides are potent inhibitors of *Mycobacterim tuberculosis*, the causative agent of tuberculosis (TB).^[@R8]^ A dual action antimicrobial agent RBx-7644 reported by the Ranbaxy Labs^[@R9]^ is a nitrofuran substituted oxazolidinone modeled after linezolid. A number of recent patents also claim utility of nitrofuran bearing compounds.^[@R10]--[@R16]^ Other nitrofuran benzimidazole compounds with good antimicrobial activity have been studied for their antileukemic properties.^[@R17]^ Herein we describe a one step synthesis of nitrofuran benzimidazoles with activity against multi-drug resistant "super bug" strains of MRSA and VRE.

Results and Discussion {#S2}
======================

Chemistry {#S3}
---------

Condensation of 5-nitro-2-furaldehyde **1** with various diamines (**2a--e**) in methanol followed by *in situ* oxidation with potassium ferricyanide in air gave substituted benzimidazoles (**3a--e**) as shown in [Scheme 1](#F4){ref-type="fig"}. The products were easily recrystallized from ethanol / water (80:20). K~2~Fe(CN)~6~, methanol, air, reflux, 16 h.

Biological assay results {#S4}
------------------------

Compounds **3a--e** were initially screened for antibiotic activity against representative Gram-negative strains of *Escherichia coli* and *Pseudomonas aeruginosa* and representative strains of Gram-positive methicillin-susceptible and methicillin-resistant *S. aureus*. The MIC values obtained are shown in [Table 1](#T1){ref-type="table"} and indicated that this initial set of compounds had good antibacterial activity. To further assess their potential, the effect of protein binding on the activity was assessed by adding 50% mouse or human serum to the MIC assays, and calculating the fold shift in MIC values. The results indicated compound specific effects ranging from 2× to 16× increases in MICs. Potential mammalian toxicity was initially assessed by screening the compounds against the Hep2 cancer cell line. Though all compounds had similar antibiotic activity, compound **3e** appeared to be the most promising of the set based on having the lowest MICs against *E. coli* (2 µg/ml) and the two Gram-positive strains (2 µg/ml) with only a 4× MIC shift in the presence of either mouse or human serum and it exhibited the least cytotoxicity against mammalian cell lines.

Based on these positive initial screening results, compound **3e** was selected for additional studies. The potency of **3e** was retained against a set of MRSA clinical isolates and the MIC values of 1--2 µg/ml obtained were similar to those of vancomycin against the same strains ([Table 2](#T2){ref-type="table"}). In an expanded panel of Gram-positive bacteria, including various drug-resistant strains, compound **3e** compared favorably to ciprofloxacin and was shown to be bactericidal by MBC analysis ([Table 2](#T2){ref-type="table"}) for **3e** the MIC = MBC indicating bactericidal activity. Compound **3e** showed significantly less activity against expanded panel of Gram-negative bacteria, suggesting selectivity for Gram-positive bacteria.

Exposure of *S. aureus* ATCC 29213 to various concentrations of **3e** and determining time-kill curves confirmed the indication that **3e** is bactericidal ([Figure 2](#F2){ref-type="fig"}). At 2, 4 and 8 times the MIC concentration, bacterial killing was observed throughout the full 24 h time course of the study. The efficacy of **3e** at the 2 -- 8 times MIC concentrations were comparable to vancomycin at four times MIC.

To further assess general toxicity and estimate a selectivity index, compound **3e** was exposed to a panel of five eukaryotic cell lines: HepG-2, HeLa, CHO, CEM-SS, and the yeast *C. albicans*. The CC~50~ values of **3e** in these studies were 37, 20, 97, 90 µM and an MIC \>64 µg/ml for *C. albicans*, respectively. While some toxicity was observed in the eukaryotic cell lines there was notable antibacterial selectivity. Microbial selectivity was also indicated by the lack of antifungal activity against *C. albicans*.

Frequency of spontaneous resistance selection by compound **3e** in three different strains of *S. aureus* (ATCC strains 29213, 700699 and 33591) was studied by exposure of the test strains to 2--4 times the MIC value of **3e**. The rates of spontaneous resistant frequencies were very low for compound **3e**: \< 2.6×10^−10^ (n=2), \<6.4×10^−10^ (n=1) and \<2.8×10^−10^ (n=1), for strains 29213, 700699, and 33591, respectively. Further attempts to induce resistance involved growing of *S. aureus* ATCC 29213 in liquid media containing compound **3e** at 0.5 -- 2 times its MIC. After eight passages only minimal (2×) resistance was observed suggesting that multiple steps will be required for the acquisition of resistance.

Mechanism of action studies were run using compound **3e** in macromolecular synthesis assays. As shown in [Figure 3](#F3){ref-type="fig"}, **3e** significantly inhibited DNA, RNA, and protein at nearly equivalent levels. This profile is consistent with the mechanism of action of compounds such as nitrofurantoin that inhibit numerous cellular processes once internalized into the bacterial cytoplasm.^[@R18]^ **3e** was also negative for hemolysis in a rat red blood cell assay that can be indicative of membrane perturbation properties (data not shown).

Compound **3e** also was shown to be reasonably stable in human, dog, rat, monkey and mouse plasma with half lives (t~1/2~) of 4.5, 5.6, 3.9, 2.0, and 3.6 h, respectively. It was also stable in the dosing vehicle (potassium phosphate at pH 7.4) with no degradation after 4 h. However, compound **3e** showed rapid metabolism in human liver and rat liver microsomes (HLM and RLM) being completely cleared within 30 min. Stability of **3e** in the human liver and rat liver S9 fractions (HLS9 and RLS9) showed rapid clearance in RLS9 (\#x0003C;30 min) but some limited stability in HLS9 with 13% remaining after 60 min of incubation and an estimated half-life of only 12.6 min.

Conclusion {#S5}
==========

Syntheses and microbiological analyses of nitrofuranyl benzimidazoles revealed that they are readily prepared, microbe-selective antibiotics with notable activity against important drug-resistant bacteria and drug-like properties appropriate for further development and consideration. Improved metabolic stability would be a key area to focus on in future lead optimization studies.

Experimental {#S6}
============

All anhydrous solvents, reagent grade solvents for chromatography and starting materials were purchased from either Aldrich Chemical Co. (Milwaulkee, WI) or Fisher Scientific (Suwanee, GA). Water was distilled and purified through a Milli-Q water system (Millipore Corp., Bedford, MA). The reactions were monitored by TLC on precoated Merck 60 F~254~ silica gel plates and visualized using UV light (254 nm). All compounds were analyzed for purity by HPLC and characterized by ^1^H and ^13^C NMR using Varian 300 MHz NMR and/or Varian 500 MHz NMR spectrometers. Chemical shifts are reported in ppm (δ) relative to the residual solvent peak in the corresponding spectra; dimethyl sulfoxide δ 2.50 and δ 39.52, methanol δ 3.31 and δ 49.00 and coupling constants (*J*) are reported in hertz (Hz) and analyzed using MestReC NMR data processing. Mass spectra values are reported as *m/z*. The liquid chromatography mass spectrum ("LC/MS") analyses were carried out on Waters ZQ instrument consisting of chromatography module Alliance HT, photodiode array detector 2996, and mass spectrometer Micromass ZQ, using a 3 × 50 mm Pro C18 YMC reverse phase column. Mobile phases: 10 mM ammonium acetate in HPLC grade water (A) and HPLC grade acetonitrile (B). A gradient was formed from 5% to 80% of B in 10 minutes at 0.7 ml/min. The MS electrospray source operated at capillary voltage 3.5 kV and a desolvation temperature 300°C. All reactions were conducted with atmospheric exposure. Solvents were removed *in vacuo* on a rotary evaporator. Abbreviations: HPLC t~R~ = HPLC retention time; DCM = dichloromethane; DMSO = dimethyl sulfoxide, DMF = dimethylformamide; ACN = acetonitrile; EtOAc = ethyl acetate; EtOH = ethanol; HOAc = acetic acid.

**2-(5-Nitrofuran-2-yl)-1-*H*-benzo\[d\]imidazole, 3a.** 5-Nitro-2-furaldehyde (**1**, 1.0 g, 7.0 mmol) and 1,2-phenylenediamine (**2a**, 658 mg, 6.0 mmol) were dissolved in 15 ml of methanol. A solution of potassium ferricyanide (4.2 g, 12.6 mmol) in 8 ml of water was added and the reaction mixture was heated to reflux for 3 h with exposure to air. The reaction mixture was cooled, filtered, and the filter pad washed with ethanol. The filtrate and washings were combined and concentrated *in vccuo*. The residue was recrystallized from EtOH:H~2~O (80:20) to give 1.34 g (7.0 mmol, 83%) of **3a** as a tan solid after filtration. Mp 225--226°C; ^1^H NMR (300 MHz, DMSO) δ 7.91 (1 H, d, *J* = 3.9 Hz), 7.66 (2 H, m), 7.48 (1 H, d, *J* = 3.7 Hz), 7.30 (2 H, m); HPLC t~R~ = 5.55 min. (\>95%), FABMS 230.3 (M+H); HRMS calcd. For C~11~H~7~N~3~O~3~, 230.0566 found 230.0561.

**5-Chloro-2-(5-nitrofuran-2-yl)-1*H*-benzo\[d\]imidazole, 3b** was prepared by reaction of **1** (304 mg, 2.1 mmol) with 4-chloro-1,2-phenlyenediamine (**2c**, 253 mg, 1.8 mmol) in 10 ml of methanol for 16 h under the same conditions used for the preparation of **3a** to give 257 mg (1.8 mmol, 55%) of **3b** as a yellow solid after recrystalization. Mp 234--235°C; ^1^H NMR (300 MHz, DMSO) δ 7.96-7.82 (1 H, bs), 7.76-7.57 (2 H, bs), 7.55-7.43 (1 H, bs), 7.37-7.23 (1 H, bs). HPLC t~R~ = 7.03 min (\>95%), FABMS 264.2 (M+H). HRMS calcd. for C~11~H~6~ClN~3~O~3~, 264.0176 found 264.0189.

**5-Fluoro-2-(5-nitrofuran-2-yl)-1*H*-benzo\[d\]imidazole, 3c** was prepared by reaction of **1** (310 mg, 2.2 mmol) and 4-fluoro-1,2-phenlyenediamine (**2c**, 230 mg, 1.8 mmol) in 10 ml of methanol for 3 h under the same conditions used for the preparation of **3a** to give 111 mg (1.8 mmol, 25%) of **3c** as a yellow-green solid after recrystalization. Mp 224--225°C; ^1^H NMR (300 MHz, DMSO) δ 7.96-7.84 (1 H, bs), 7.75-7.60 (1 H, bs), 7.58-7.38 (2 H, bs), 7.27-7.08 (1 H, bs). HPLC t~R~ = 6.07 min (\>95%). FABMS 248.3 (M+H). HRMS calcd. for C~11~H~6~FN~3~O~3~, 248.0471 found 248.0474 found.

**7-Methyl-2-(5-nitrofuran-2-yl)-1*H*-benzo\[d\]imidazole, 3d** was prepared by reaction of **1** (407 mg, 2.8 mmol) 2,3-diaminotoluene (**2f**, 300 mg, 2.4 mmol) in 10 ml of methanol for 3 h under the same conditions used for the preparation of **3a** to give 519 mg (2.8 mmol, 75%) of **3d** as a brown-tan solid after recrystalization. Mp 222--223°C; ^1^H NMR (300 MHz, DMSO) δ 7.82 (1 H, d, *J* = 3.9 Hz), 7.40 (2 H, m), 7.11 (1 H, t, *J* = 7.6, 7.6 Hz), 7.01 (1 H, d, *J* = 6.8 Hz), 2.61 (3H, s); HPLC t~R~ = 6.32 min (\>95%). FABMS 244.4 (M+H). HRMS calcd. for C~12~H~9~N~3~O~3~, 244.0722 found 244.0729.

**2-(5-Nitrofuran-2-yl)-3*H*-benzo\[d\]imidazole-4ol, 3e** was prepared by reaction of **1** (278 mg, 2.6 mmol) and 2,3-diaminophenol (**2e**, 300 mg, 2.4 mmol) in 10 ml of methanol for 16 h under the same conditions used for the preparation of **3a** to give 340 mg (2.6 mmol, 53%) of **3e** as a gold-orange solid after recrystalization. Mp \>295°C; ^1^H NMR (300 MHz, DMSO) δ 7.90 (1 H, m), 7.42 (1 H, m), 7.06 (2 H, m), 6.59 (1 H, m); HPLC t~R~ = 4.73 min (\>95%). FABMS 246.4 (M+H); HRMS calcd. for C~11~H~7~N~3~O~4~, 246.0515 found 246.0504.

Determination of *in Vitro* Antimicrobial Activity {#S7}
==================================================

MICs were determined as outlined by the CLSI (CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. CLSI document M7-A7, 7th 22 ed., vol. 26, 23 no. 2. CLSI, Wayne, PA). The MIC was defined as the lowest concentration of each compound that resulted in inhibition of bacterial visible growth after incubation at 37°C for 18--24 h. All bacterial strains used in this work were obtained from either the American Type Culture Collection (ATCC) or the Achillion Pharmaceuticals Culture Collection.

Determination of Bactericidal Activity {#S8}
======================================

Bactericidal activity was determined by two independent methods. Minimal bactericidal concentrations (MBCs) were determined by plating 10 µl of inoculated medium from MIC wells that showed no visible bacterial growth. The compound concentrations from the wells that resulted in no growth on the agar plates (\>99.9% killing) were designated as the MBCs. Time-kill studies were also done. Briefly, all strains were cultured overnight at 37°C, diluted into fresh medium, grown to exponential phase, and then diluted again in medium to adjust cell densities to approximately 10^7^ CFU/ml. Compounds were then added at concentration multiples of the MIC. Rates of killing were determined by measuring the reduction in viable bacteria (log~10~ CFU/ml) at 0, 1, 2, 4, 6, and 24 h at fixed concentrations of compound. Experiments were performed in duplicate. If plates contained fewer than ten CFU/ml, the number of colonies was considered to be below the limit of quantitation. Samples of culture containing compound were diluted at least 10-fold to minimize drug carryover to the agar plates.

Macromolecular synthesis assays {#S9}
===============================

The effects of compound **3e** and control compounds ciprofloxacin (DNA synthesis), rifampicin (RNA synthesis) and chloramphenicol (protein synthesis) on DNA, RNA, and protein synthesis in bacteria were determined using radiolabeled precursors \[3H\]-thymidine (DNA), \[3H\]-uracil (RNA), \[310 H\]-leucine (protein) in mid-exponential-phase cultures (\~10^8^ CFU/ml) of S. aureus ATCC 29213 in a chemically-defined medium as previously described.^[@R19]^ Final concentrations of 5 μCi/ml for thymidine and 2.5 μCi/ml for each of the other precursors were added to cultures immediately before the addition of antibiotics (10× MIC). Negative controls for the macromolecular assays consisted of all reaction materials with no antibiotics added and the resulting counts were used as the 100% values. After an additional 20 min incubation at 37°C in the presence of antibiotics, samples were removed for trichloroacetic acid precipitation and subsequent scintillation counter analyses for determination of radioactive incorporation into DNA, RNA, or protein, and the data expressed as a percent inhibition of incorporation into a drug-free control.

Cytotoxicity Assay {#S10}
==================

Cytotoxicity is reported as a CC~50~ value, defined as the concentration of drug that results in toxicity to 50% of the cells compared to untreated control cells. Cytotoxicity was measured by Alamar Blue reduction as the amount of fluorescence or absorbance is proportional to the number of living cells and corresponds to the cells metabolic activity. Damaged and nonviable cells have lower innate metabolic activity and thus generate a proportionally lower signal than healthy cells. Hep2 (human laryngeal carcinoma) HepG-2 (human hepatocellular carcinoma), HeLa (cervical carcinoma), CHO (Chinese hamster ovary), CEM-SS (human T lymphoblastoid) cell lines were incubated with drug concentrations at 37° C for 72 h to generate seven-point CC~50~ data.
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  ----------------------------------------------------------------------------------------------------------
  Compd    Mol.\    Calc.\   *E.*\    MSSA   MRSA   PA     MSSA +\   Fold\    MRSA +\   Fold\    Hep2\
           Wt.      ClogP    *coli*                        50%\      Shift\   50%\      Shift\   Toxicity\
                                                           mouse\    Mouse    human\    Human    (CC~50~\
                                                           serum              serum              µM)
  -------- -------- -------- -------- ------ ------ ------ --------- -------- --------- -------- -----------
  **3a**   229.19   2.84     2        4      2      \>64   4         2×       8         4×       5.1

  **3b**   263.64   3.60     8        4      2      \>64   16        8×       32        16×      5.0

  **3c**   247.18   3.03     4        4      4      \>64   16        4×       8         2×       3.1

  **3d**   243.22   3.34     4        4      2      \>64   8         4×       16        8×       1.7

  **3e**   245.19   2.88     2        2      2      \>64   8         4×       8         4×       31.6
  ----------------------------------------------------------------------------------------------------------

E. coli, *Escherichia coli* ATTC 25922; MSSA, methicillin-susceptible *S. aureus* ATCC 29213; MRSA, methicillin-resistant *S. aureus* ATCC 700699; PA, *Pseudomonas aeruginosa* ATCC 27853. CC~50~ is defined as the concentration of drug that results in toxicity to 50% of the cells compared to untreated control cells.

  MIC (MBC) MRSA Panel (µg/ml)                                            
  ------------------------------------------- --------------- ----------- -------------------
  Organism                                    Strain ID       3e          Vancomycin
  *S.aureus*                                  ATCC 33591      2 (2)       1
  *S.aureus*                                  COL             1           1
  *S.aureus*                                  BK 2384         1           1
  *S.aureus*                                  BSA 643         1 (2)       1
  *S.aureus*                                  BSA 678         1           1
  *S.aureus*                                  NY 2746         2           1
  *S.aureus*                                  ACH-0231        2           2
  *S.aureus*                                  ACH-0232        2           1
  **MIC (MBC) Gram-positive Panel (µg/ml)**                               
  **Organism**                                **Strain ID**   **3e**      **Ciprofloxacin**
  *S. aureus* (MS)                            ATCC 29213      2           0.25
  *S.epidermidis (MS)*                        SE42            1 (1)       0.25
  *S.haemolyticus (MS)*                       ACH-0013        0.5 (0.5)   8
  *E.faecalis*                                ATCC 29212      1           1
  *E.faecium*                                 ATCC 49032      4 (4)       8
  *S.epidermidis (FQR)*                       ACH-0082        4           64
  *E.faecalis (VR)*                           ATCC 700802     1           0.5
  *E.faecium (VR)*                            ATCC 700221     4           \>64
  **MIC Gram-negative Panel (µg/ml)**                                     
  **Strain**                                  **Strain ID**   **3e**      **Ciprofloxacin**
  *E.cloacae*                                 ACH-0008        4           0.031
  *K.pneumoniae*                              ATCC 13883      8           0.063
  *S.marcescens*                              ACH-0009        16          0.063
  *S.typhimurium*                             ATCC 14028      4           0.031
  *A.baumanii*                                ATCC 9957       \>64        \>2
  *E.coli*                                    1GC2            16          0.5
  *E.coli*                                    FQR 362265      4           16
  *P.aeruginosa*                              FQR 467296      \>64        8
  *S.maltophila*                              ATCC 13637      \>64        0.25

MS, methicillin-susceptible; FQR, fluoroquinolone-resistant; VR, vancomycin-resistant Gram-negative bacteria: *Enterobacter cloacae, Klebsiella pneumoniae, Serratia marcescens, Salmonella typhimurium, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, Stenotrophomonas maltophila*
